Live Cell Encapsulation: Drug Delivery is the Largest Market Growth Contributor

What This Report Will Provide?

This study involved four major activities in estimating the current size of the live cell encapsulation market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Expected Revenue Growth:

[136 Pages Report] The live cell encapsulation market is projected to grow to USD 303 million by 2024 from USD 250 million in 2018, at a CAGR of 3.2%

Major Growth Boosters:

Growth in the live cell encapsulation market is primarily driven by factors such as the increasing public-private investments to support product development, increasing research to establish the clinical efficacy of cell encapsulation technologies, and rising public awareness related to the clinical role of encapsulated cells in disease management.

Download PDF Brochure:

Recent Developments:

In January 2015, BioTime, Inc. launched the pluripotent cells for research, drug discovery, and regenerative medicine therapies. This helped the company to improve its position in the live cell encapsulation market.

Cell encapsulation is undertaken for the manufacturing of tablets, capsules, and parenteral dosage forms for effective drug delivery. The growth of this segment includes the increasing adoption of cell encapsulation for drug delivery is mainly due to its procedural benefits (such as improved efficacy, reduced toxicity, and improved patient compliance & convenience).

Key Questions Addressed in The Report:

1. Who are the top 10 players operating in the global live cell encapsulation market?
2. What are the drivers, restraints, opportunities, and challenges in the live cell encapsulation Industry?
3. What are the opportunities for stakeholders and provide details of the competitive landscape for key players?
4. What will be growth of live cell encapsulation in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa?

Request Sample Pages:

Regional Growth Analysis:

North America is one of the major revenue-generating regions in the live cell encapsulation market. The increasing public-private investments in the live cell encapsulation industry in the US and Canada, ongoing technological advancements in live cell encapsulation, and the presence of major market players in the region are the major factors driving the growth of the live cell encapsulation market in North America.

Key Market Players:

BioTime, Inc. (US), Viacyte, Inc. (US), and Living Cell Technologies Ltd. (Australia) were the top three players in the live cell encapsulation market. Other prominent players operating in this market include Sigilon Therapeutics, Inc. (US), Evonik Industries (Germany), BÜCHI Labortechnik AG (Germany), Blacktrace Holdings Ltd (UK), and Sernova Corporation (Canada), among others. Furthermore, the key players in the developmental pipeline products in this market include Neurotech Pharmaceuticals, Inc. (US), Gloriana Therapeutics (US), Kadimastem (Israel), Beta-O2 Technologies, Inc. (Israel), Defymed (France), and Altucell, Inc. (US), among others.

BioTime, Inc. (US) dominated the live cell encapsulation market in 2017. The company has a strong geographic presence across the regions such as US, Australia, New Zealand, Israel, Canada, China, Japan, and Taiwan. BioTime, Inc. mainly focuses on product commercialization to further strengthen its position in the live cell encapsulation market.